JamesM.CoghillJr.MD

Assistant Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Dr. Coghill is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Unc Chapel Hill, Division Of Hematology Oncology
Cb# 7305, 3009 Old Clinic Building
Chapel Hill, NC 27712
Phone+1 919-966-6767

Fax+1 919-966-0188

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2007
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Virginia Commonwealth University School of MedicineClass of 2001

PubMed

3 citations
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.
Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore
The Lancet. Haematology. 2024-05-01
7 citations
Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD.
Danny W. Bruce, Oleg Kolupaev, Sonia J. Laurie, Hemamalini Bommiasamy, Heather E. Stefanski
Blood Advances. 2021-11-23
36 citations
Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
Matthew C. Foster, Barbara Savoldo, Winnie W. Y. Lau, Clio Rubinos, Natalie S Grover
Blood. 2021-06-10

Abstracts/Posters

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD
James M. Coghill Jr., 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Targeting Cc-Chemokine Receptor 7 For The Prevention Of Graft-Versus-Host DiseaseNational Heart, Lung, And Blood Institute2012
The Role Of The Chemokine Receptos CCR4 And CCR7 In Graft-Versus-Host DiseaseNational Institute Of Allergy And Infectious Diseases2008–2009